NIH Investigating Why Patients Relapse After Taking Pfizer’s COVID Antiviral Pill, Paxlovid . Children’s Health Defense
National Institutes of Health (NIH) researchers said they will investigate how often and why coronavirus levels rebound in some patients who complete a five-day course of Pfizer’s COVID-19 antiviral pill, Paxlovid.
“It is a priority,” Clifford Lane, deputy director for clinical research at the National Institute of Allergy and Infectious Diseases, told Bloomberg. It’s “a pretty urgent thing for us to get a handle on.”
Lane said the agency is discussing with scientists at the Centers for Disease Control and Prevention possible epidemiological and clinical studies to examine post-Paxlovid rebound.